Completed PHASE2 INTERVENTIONAL NCT00262613

Sodium Pyruvate Therapy in COPD Patients

Long-Term Use of Inhaled Sodium Pyruvate for the Treatment of Chronic Obstructive Pulmonary Disease

Sponsor: Cellular Sciences, inc.

Conditions Chronic Obstructive Pulmonary Disease (COPD)

Interventions sodium pyruvate in 0.9% sodium chloride solution

Updated 6 times since 2017 Last updated: May 25, 2006 Started: Sep 30, 2004 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00262613, this PHASE2 trial focuses on Chronic Obstructive Pulmonary Disease (COPD) and remains completed. Sponsored by Cellular Sciences, inc., it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Oct 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cellular Sciences, inc.
Emphycorp

Data source: Emphycorp

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Britain, United States
• New Haven, United States